Home
MeiraGTx Limited

MeiraGTx Limited Market Share Analysis for July 2026

MeiraGTx is developing an investigational gene therapy to deliver the glutamic acid decarboxylase gene to the brain to improve symptoms in Parkinson’s disease.

Health > Biotechnology and Pharmaceuticals

Domainmeiragtx.com

Year Founded2015

Employees201 - 500

Annual Revenue$50M - $75M

MeiraGTx Limited

MeiraGTx Limited (including company regionals)

meiragtx.com

See more website traffic and engagement information

MeiraGTx Limited Revenue up to July 2026 is 50M - 75M

revenue generated by MeiraGTx Limited top domains

MeiraGTx Limited top domains revenue over 3 years

Revenue for MeiraGTx Limited top domains

meiragtx.com50M - 75M

See more with Sales Intelligence

Total visits to MeiraGTx Limited's top domains

Understand MeiraGTx Limited market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

meiragtx.com10.1K

See more with Sales Intelligence

Avg. visit duration in MeiraGTx Limited's top domains

Analyze MeiraGTx Limited engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

meiragtx.com00:00:08

See more with Sales Intelligence

Avg. pageviews on MeiraGTx Limited's top domains

See how MeiraGTx Limited keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

meiragtx.com1.65

See more with Sales Intelligence

MeiraGTx Limited top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by MeiraGTx Limited

These are the website technologies, by industry, used by MeiraGTx Limited top domains

Widget (4)

Twemoji

Audio Video Media (3)

YouTube

Email Services (2)

Sendgrid

Mobile (2)

Meta Viewport

More Technologies

6

See all

News & Signals from MeiraGTx Limited

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMeiraGTx Limited had revenue of $321M on Aug 13th '26.* MeiraGTx reported quarterly EPS of $1.71, far above the consensus estimate of a $0.46 loss, alongside revenue of $321.43 million versus estimates of roughly $0.70 million.

NewsMeiraGTx Limited is developing clinical-grade gene therapy vector.London-based biotechnology company MeiraGTx subsequently partnered to develop a clinical-grade gene therapy vector for human use.

NewsMeiraGTx Limited was planning to receive financing of $375M in financing on Jul 10th '26.* Oberland Capital will provide as much as $375 million in financing and up to $25 million in the form of an equity investment for MeiraGTx.